Founders
Building the Future of Benefit-Risk Assessment
Romain Clement, PhD
Founder & Chief Executive Officer
PharmD, PhD Pharmacoepidemiology (Sorbonne)
Romain founded ArcaScience in 2018 after completing his PhD in pharmacoepidemiology at Sorbonne University. Following successful treatment for brain cancer, he recognized the critical need for structured, AI-driven tools in benefit-risk assessment. Prior to founding ArcaScience, Romain conducted post-doctoral research at ANSM (French Medicines Agency) on signal detection methodologies and served as a pharmacovigilance consultant to multiple pharmaceutical companies.
LinkedIn Profile →
Marie Dubois, PhD
Co-Founder & Chief Technology Officer
PhD Computer Science (École Polytechnique)
Marie co-founded ArcaScience and leads platform engineering and AI model development. She completed her PhD at École Polytechnique focused on natural language processing for biomedical text mining. Before ArcaScience, Marie was a senior research scientist at INRIA, where she developed machine learning methods for pharmacovigilance signal detection. She holds 8 patents in AI-driven healthcare analytics and has published 20+ peer-reviewed papers.
LinkedIn Profile →Executive Leadership
Experienced Leaders from Pharma, Regulatory, and Technology
Dr. Jean-Pierre Moreau
Chief Scientific Officer
MD, PhD Clinical Pharmacology
Former VP Drug Safety at Sanofi with 20+ years in pharmacovigilance. Led benefit-risk assessments for 15+ regulatory submissions across FDA, EMA, and PMDA. Expert in BRAT framework implementation.
LinkedIn →
Sarah Chen
Chief Operating Officer
MBA Stanford, BS Engineering MIT
Former Director of Operations at a top-10 pharma company. Led SaaS platform deployment for global regulatory teams. Expert in pharmaceutical enterprise software scaling and GxP compliance operations.
LinkedIn →
David Müller, PhD
VP Engineering
PhD Computer Science (ETH Zurich)
Former principal engineer at Google Health. Led development of FHIR-compliant data pipelines processing 10B+ clinical records. Expert in distributed systems architecture and healthcare data interoperability.
LinkedIn →
Dr. Amanda Foster
VP Regulatory Science
PharmD, RAC (Regulatory Affairs Certified)
Former FDA CDER medical reviewer with 12+ years evaluating NDA/BLA submissions. Deep expertise in safety assessment methodologies, advisory committee preparation, and FDA benefit-risk framework guidance.
LinkedIn →
Dr. Priya Sharma
VP Data Science & AI
PhD Biostatistics (Johns Hopkins)
Former lead data scientist at AstraZeneca, where she developed predictive models for drug safety signal detection. Published 30+ papers on Bayesian methods, causal inference, and AI applications in pharmacovigilance.
LinkedIn →
Michael O'Brien
VP Commercial
MBA Wharton, BS Biology Cornell
Former VP Business Development at IQVIA. Led enterprise software partnerships with 15+ top-20 pharmaceutical companies. Expert in pharmaceutical technology adoption, value selling, and regulatory software procurement.
LinkedIn →Scientific Advisory Board
World-Class Researchers Guiding Our Scientific Direction
Our Scientific Advisory Board brings together leading experts in pharmacoepidemiology, regulatory science, AI research, and clinical medicine to guide ArcaScience's platform development and research priorities.
Prof. Nicholas Tatonetti
Columbia University
Associate Professor, Biomedical Informatics
Expertise
Drug-drug interaction detection, AI safety signal methods, pharmacovigilance data mining
120+ publications | h-index: 45
Dr. Sabine Straus
Utrecht University Medical Center
Chair, EMA Pharmacovigilance Committee (PRAC)
Expertise
Regulatory pharmacovigilance, EMA guidance frameworks, benefit-risk methodology
180+ publications | h-index: 52
Prof. Mihaela van der Schaar
University of Cambridge
Professor of Machine Learning & Medicine
Expertise
Machine learning for healthcare, causal inference, interpretable AI for clinical decision support
250+ publications | h-index: 67
Dr. Joshua Cohen
Tufts Medical Center
Director, HEOR & Market Access Research
Expertise
MCDA for health technology assessment, value frameworks, ICER methodology, HTA submissions
95+ publications | h-index: 38
Prof. Antoine Pariente
University of Bordeaux
Head, Regional Pharmacovigilance Centre
Expertise
Spontaneous reporting databases, disproportionality analysis, signal validation methodologies
140+ publications | h-index: 44
Dr. Russ Altman
Stanford University
Professor, Bioengineering & Genetics
Expertise
Pharmacogenomics, computational biology, AI applications in precision medicine and drug safety
300+ publications | h-index: 89